Aptose Biosciences Inc. (APTO) CEO William G. Rice Buys 10,000 Shares

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice purchased 10,000 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was purchased at an average cost of $1.85 per share, for a total transaction of $18,500.00. Following the purchase, the chief executive officer now directly owns 153,014 shares in the company, valued at $283,075.90. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

NASDAQ:APTO opened at $1.83 on Monday. The stock has a market capitalization of $73.66 million, a P/E ratio of -2.13 and a beta of 1.61. Aptose Biosciences Inc. has a 52-week low of $1.57 and a 52-week high of $4.55.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Research analysts expect that Aptose Biosciences Inc. will post -0.72 EPS for the current year.

Several analysts have issued reports on the company. Zacks Investment Research downgraded Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, March 26th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Royal Bank of Canada assumed coverage on Aptose Biosciences in a research note on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target on the stock. Oppenheimer assumed coverage on Aptose Biosciences in a research note on Thursday, January 24th. They issued an “outperform” rating and a $6.00 price target on the stock. Finally, Citigroup assumed coverage on Aptose Biosciences in a research note on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Aptose Biosciences currently has an average rating of “Buy” and an average price target of $5.71.

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in shares of Aptose Biosciences in the first quarter valued at about $198,000. Geode Capital Management LLC acquired a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $33,000. Noven Financial Group Inc. acquired a new stake in shares of Aptose Biosciences in the fourth quarter valued at about $27,000. Patriot Financial Group Insurance Agency LLC increased its position in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 5,890 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Aptose Biosciences by 1,130.9% in the third quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock valued at $477,000 after acquiring an additional 168,501 shares during the last quarter. 7.68% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Aptose Biosciences Inc. (APTO) CEO William G. Rice Buys 10,000 Shares” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/aptose-biosciences-inc-apto-ceo-william-g-rice-buys-10000-shares.html.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading: How to invest in a bear market

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.